Alps Group Inc (ALPS) is a Malaysia-based biotechnology and wellness company that went public on Nasdaq in October 2025 through a merger with a SPAC (special purpose acquisition company). Unlike most coverage targets, the $1 price objective examined here is not an analyst forecast. It is the minimum bid price the stock must reclaim to satisfy Nasdaq's continued-listing rules.
Alps Group has essentially no usable sell-side coverage. MarketBeat's forecast page lists no attributable price targets and a consensus target of "N/A," while the only rating on record is a "Sell (E+)" from Weiss Ratings, most recently reiterated in October 2026. Because no credible, current analyst price targets exist to average, this article uses the fallback method: a price objective that is actually being discussed in the public market.
That objective is $1. On May 15, 2026, Nasdaq notified the company that its shares had fallen below the $1.00 minimum bid price required for continued listing, with a compliance deadline of November 11, 2026. Reclaiming $1 is therefore the single most concrete, widely referenced price milestone for this stock. It is a listing-compliance target, not a valuation-based analyst consensus, and it should not be read as a prediction that shares will reach that level.
Shares have recently traded near $0.33, down more than 90% over the past year from post-merger levels that reached double digits. With a market capitalization of roughly $54 million, Alps Group is a micro-cap whose shares have been exceptionally volatile.
A move from about $0.33 to $1 represents an approximate 200% gain—a very large move by any standard. The company is loss-making: fiscal 2026 revenue (year ended March 2026) rose about 44% to roughly $4.9 million, but the business still posted a net loss of about $2.1 million, with limited cash on hand. The path toward $1 would likely depend on regaining compliance through either sustained share-price appreciation or a reverse stock split, a step management may weigh if organic recovery proves insufficient.
From a technical standpoint, $1 now functions as the dominant resistance level and psychological threshold because of the listing requirement. Above that, longer-term chart context shows shares previously traded in the single digits, leaving limited nearby resistance in between. On the downside, the 50-day and 200-day moving averages have sat near $0.37 and $0.69 respectively, while the 52-week low near $0.23 marks a key support zone. The stock's persistent downtrend underscores that any recovery would need sustained buying and improved fundamentals to hold.
The $1 objective is tied to a specific listing deadline rather than a standard 12-month research horizon, so the near-term catalyst is the Nasdaq compliance process itself. Investors should watch for announcements on reverse splits or compliance extensions, upcoming earnings and revenue updates, new collaboration or financing news, and any changes in institutional ownership. Broader risk appetite for speculative micro-cap biotech names will also matter.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, low-liquidity ticker such as ALPS, tools like these can help traders surface opportunities, keep track of positions, and spot changing trends more efficiently than manual screening. Investors looking to apply a systematic approach may find it useful to explore these signals.
Can Alps Group reach $1? The objective is real and clearly defined—it is the Nasdaq minimum bid price the company must reclaim, most directly by its November 2026 compliance deadline—but it is not an analyst price target, and no verifiable consensus exists to support or contradict it. Reaching $1 from roughly $0.33 would require a gain of about 200%, a very large move for a loss-making micro-cap with thin cash and mounting listing pressure. Growth in revenue and new diagnostic collaborations provide a foundation, while delisting risk, dilution, and weak liquidity are serious obstacles. Investors should monitor the compliance process, financing decisions, and operating results rather than treat $1 as an expectation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that ALPS and PRLD have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALPS and PRLD's prices will move in lockstep.
| Ticker / NAME | Correlation To ALPS | 1D Price Change % | ||
|---|---|---|---|---|
| ALPS | 100% | -3.03% | ||
| PRLD - ALPS | 28% Poorly correlated | N/A | ||
| QURE - ALPS | 28% Poorly correlated | -0.35% | ||
| SRPT - ALPS | 27% Poorly correlated | -4.76% | ||
| TCRX - ALPS | 26% Poorly correlated | +1.98% | ||
| STOK - ALPS | 25% Poorly correlated | -1.80% | ||
More | ||||